Fussen

This research aims to assess how satisfied people with Multiple Sclerosis (MS) are after receiving subcutaneous (under the skin) injections of ocrelizumab over a period of 12 months. The study focuses on participants diagnosed with relapsing-remitting MS (RMS) or primary progressive MS (PPMS) according to 2017 McDonald criteria, who are starting ocrelizumab treatment for the first time. The main goal is to understand participant satisfaction using a special questionnaire designed for subcutaneous therapy administration. Participants will receive ocrelizumab as an injection under the skin, with the exact dosing and schedule determined by their treating physician following local medical guidelines. This observational study does not change standard care but monitors patients throughout their treatment with ocrelizumab. During the study, participants will complete the Therapy Administration Satisfaction Questionnaire for subcutaneous treatment after 12 months to measure their satisfaction. Researchers will also observe and record any relevant clinical information. The total study duration for each participant is 12 months, during which their experience and outcomes with ocrelizumab are carefully tracked.

Researchers are evaluating the effects of cold water hydrotherapy on patients suffering from Post-COVID Syndrome, a condition marked by symptoms such as persistent fatigue, autonomic imbalance, microcirculatory problems, and ongoing low-grade inflammation. The study aims to compare how this hydrotherapy influences quality of life against usual care without hydrotherapy treatment. This randomized controlled trial focuses on the potential benefits of cold water applications in improving these post-viral symptoms. Participants will undergo a 3-week program where they receive cold water hydrotherapy treatments lasting 5 to 10 minutes each, four times daily. These treatments use various washing and pouring methods and are customized to each individual's response. After this initial phase, participants continue with once-daily hydrotherapy for a 6-month follow-up period to monitor longer-term effects. Throughout the study, participants will provide baseline demographic and health information, including their post-COVID symptoms, smoking history, comorbidities, and severity of their initial COVID-19 illness. Evaluations include autonomic function testing, work ability assessments, and recording sick leave related to Post-COVID. The main outcome measured is health-related quality of life, assessed from baseline through the end of the 3-week program using the Short Form-12 Health Survey. Researchers will track these factors to understand how hydrotherapy might aid recovery.